Madrigal ( (MDGL) ) has released its Q1 earnings. Here is a breakdown of the information Madrigal presented to its investors.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs. The company is known for its FDA-approved drug, Rezdiffra, which targets moderate to advanced liver fibrosis in MASH patients.
In its first-quarter 2025 earnings report, Madrigal Pharmaceuticals announced net sales of $137.3 million for Rezdiffra, marking a significant milestone as the first FDA-approved treatment for MASH. The company also highlighted its strong cash position and strategic appointments to its leadership team.
Key financial metrics from the report include operating expenses of $216.6 million and a decrease in research and development expenses to $44.2 million, attributed to changes in accounting for inventory costs and reduced clinical trial expenses. The company also reported an increase in selling, general, and administrative expenses due to commercial launch activities for Rezdiffra. Additionally, Madrigal has a robust presence at the upcoming EASL Congress, where it will present new data on Rezdiffra’s impact on liver stiffness and portal hypertension.
Looking ahead, Madrigal Pharmaceuticals is optimistic about Rezdiffra’s potential as a foundational therapy for MASH, with expectations of a regulatory decision from the European Medicines Agency mid-year. The company continues to focus on expanding its reach and impact in the MASH treatment landscape.